Randomized controlled trial on the efficacy of bloodletting for arterial hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00004265

Enrollment

Registered

2012-07-23

Start date

2012-07-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I10.0

Interventions

Group 1: In the intervention group there will be two phlebotomies withdrawing 500 ml of blood each time, one at the beginning of the study and another after 6 weeks time. Group 2: untreated control-g

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: - between 30 and 70 years of age; - manifest arterial hypertension, NICE/WHO stadium I (= 140-159 mmHg syst. and 90-99mmHg diast.) that hasn't been treated pharmacologically yet; - Patients in Stadium II (= 160-179 mmHg syst. and 100-109 mmHg diast.) can only be included if they reject pharmacologic therapy because of intolerances to drugs (twofoldly documented in specialist-consultation by cardiologist or nephrologist).

Exclusion criteria

Exclusion criteria: - demonstrably elevated cardiovascular risk with prevalence of at least one of the following 4 risk factors: 1) known coronary heart disease 2) renal insufficiency with microalbuminuria (precluded by laboratory-analysis) 3) known diabetes mellitus 4) known retinopathy; - elevated cerebrovascular risk with 1) known stenosis of common carotid artery, or anamnesis with 2) transient ischemic attack or 3) cerebral infarction - consisting coagulation disorder, known hemophilia or pharmacological anticoagulants; - pregnancy - patients with acute infections - patients with consisting anemia

Design outcomes

Primary

Measure	Time frame
Alteration of the 24-hour bloodpressure measurement (24h-average), baseline vs. termination after 8 weeks	—

Secondary

Measure	Time frame
Systolic bloodpressure after resting-period (average of 3 measurements), diastolic bloodpressure after resting-period (average of 3 measurements), heart rate after resting-period (average of 3 measurements), blood lipids / cardiovascular risk markers: 1. serum ferritin, 2. hematocrit, 3. serum iron, 4. triglycerides, 5. LDL cholesterol, 6. HDL cholesterol; baseline vs. termination after 8 weeks	—

Countries

Germany

Contacts

Public ContactSabine Saalfeld

Immanuel Krankenhaus Berlin Wannsee Hochschulambulanz für Naturheilkunde der Charité Universitätsmedizin Abteilung für Naturheilkunde

S.Saalfeld@immanuel.de030/80505 -659

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026